MedTrace Logo

Effects of Oxytocin on Cognitive and Reactive Fear

NCT04292444 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-03-12

No results posted yet for this study

Summary

The study examines the (sub)regional specificity of anxiolytic oxytocin (OXT) effects on emotional face processing and reactive and cognitive fear. Preliminary data indicate that the Receptor for Advanced Glycation End Products (RAGE) may regulate oxytocin transport into the brain. Thus, the study aims to replicate previous observations of oxytocin effects on the processing of fearful faces in the centro-medial amygdala and to assess whether a RAGE polymorphism (-374 T/A: rs1800624; TT vs. TA/AA), that has been shown to alter transcriptional activity, modulates anxiolytic OXT effects.

Conditions

  • Oxytocin

Interventions

DRUG

Oxytocin nasal spray

Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.

DRUG

Placebo

The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Rene Hurlemann, MSc, MD, PhD · University of Oldenburg

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04292444 on ClinicalTrials.gov